Developing a new immunotherapy using engineered T cells for pancreatic cancer
Engineering CD4+ T cells to develop a novel immunotherapy for pancreatic cancer
This study is looking at a new way to help people with pancreatic cancer by using specially modified immune cells that can better target and fight the cancer, with the hope of improving treatment options and outcomes for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10998579 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for pancreatic ductal adenocarcinoma (PDAC), a type of cancer with very limited survival rates. The approach involves engineering CD4+ T cells to express a specific receptor that targets mesothelin, a protein found on the surface of pancreatic cancer cells. By enhancing these T cells with an enzyme that can alter the tumor environment, the researchers aim to improve the effectiveness of immunotherapy for patients with PDAC. The study will assess how these engineered T cells can remodel the tumor microenvironment and boost the immune response against the cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients suffering from pancreatic cancer.
How similar studies have performed: Previous research has shown promise in using engineered T cells for other cancers, but this specific approach for pancreatic cancer is novel and untested.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Geitgey, Delaney Kate — Emory University
- Study coordinator: Geitgey, Delaney Kate
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.